Biogen stopped updating investors on the number of PML cases at the end of July, saying it wanted to focus on the drug's benefits, and would update the medical community at scientific meetings.

Biogen spokeswoman Naomi Aoki declined to comment on whether the figure of 23 cases were consistent with its own records, and she reiterated that the company would not update the public case by case.


*According to Reuters*